Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.
The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 96% confidence.¹
Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).
Our mission is to create a paradigm shift in cardiovascular diagnostics through rapid, reliable and reassuring evaluation of chest pain patients with suspected heart disease.
Our vision is that everyone who needs a CADScor®System assessment should be able to have one in a timely manner.
An AI-powered acoustic diagnostic aid to rule out coronary artery disease in 10 minutes.
Please visit our contact page to get in touch.
- US user manual v.12.5, prevalence 10,7%, algorithm version US3.2